Fig 1.
(A) 4F-PCC in rabbits with dilutional coagulopathy, using modified Wessler model of venous stasis-induced thrombosis; (B) 4F-PCC in rabbits with edoxaban-induced coagulopathy using modified Wessler model of venous stasis-induced thrombosis; (C) 4F-PCC in rats, using a ferric chloride-induced model of arterial thrombosis. Haemodilution was used only in the experiments indicated. 4F-PCC, 4-factor prothrombin complex concentrate; h, hours; min, minutes; t, time.
Fig 2.
Thrombus score and thrombus weight: Dose-response for 4F-PCC, aPCC, and rFVIIa.
(A) 4F-PCC thrombus score; (B) 4F-PCC thrombus weight; (C) aPCC thrombus score; (D) aPCC thrombus weight; (E) rFVIIa thrombus score; (F) rFVIIa thrombus weight. Data for venous stasis-induced thrombosis 10 minutes after the end of PCC, aPCC or rFVIIa infusion. Figure shows mean (standard deviation). * indicates a therapeutic dose.
Fig 3.
Time course of response to 4F-PCC.
(A) thrombus score; (B) thrombus weight. ND, not detectable. Data for venous stasis-induced thrombosis at the indicated timepoints after the end of 4F-PCC (300 IU/kg) infusion. Figure shows mean (standard deviation).
Table 1.
(A) 4F-PCC in rabbits with dilutional coagulopathy, using modified Wessler model of venous stasis-induced thrombosis; (B) 4F-PCC in rabbits with edoxaban-induced coagulopathy using modified Wessler model of venous stasis-induced thrombosis; (C) 4F-PCC in rats, using a ferric chloride-induced model of arterial thrombosis.
Fig 4.
Data for venous stasis-induced thrombosis following end of PCC infusion.
(A) Thrombus score and (B) thrombus wet weight at 30 minutes following administration of edoxaban (600 μg/kg) or saline followed by 4F-PCC and venous stasis in rabbits; (C) thrombus score and (D) thrombus wet weight over time following administration of edoxaban 600 μg/kg or saline followed by 4F-PCC (300 IU/kg) and venous stasis in rabbits. Figure shows median (range). **P<0.01.
Fig 5.
ATR assay: Comparison of 4F-PCC, aPCC and rFVIIa impact on thrombosis following FeCl3 treatment.
Incidence of thrombosis after 5% FeCl3 injury and treatment with 4F-PCC, aPCC or rFVIIa.